Andere Sprachen Sarepta Therapeutics, Inc.

Aktien

A1J1BH

US8036071004

SRPT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
124,2 ^USD	+6,09 %		+5,39 %	+28,85 %

21.03.	FDA gibt grünes Licht für Italfarmacos Medikament gegen seltene Muskeldystrophie	RE
12.03.	Transcript : Sarepta Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:05 PM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results	24.04.
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition	04.04.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - March 29, 2024	01.04.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	29.03.
FDA greenlights Italfarmaco's drug for rare muscular dystrophy	21.03.
Sarepta Therapeutics Announces Call for Applications for the 2024 LGMD Grant Award Program	20.03.
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing	12.03.
Sarepta Therapeutics Insider Sold Shares Worth $385,480, According to a Recent SEC Filing	07.03.
Sarepta Therapeutics to Present at Upcoming Investor Conferences	04.03.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	01.03.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.03.
Sarepta Therapeutics' Regulatory Drug Review Underpins Prospects for Rally, RBC Says	29.02.
Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program	29.02.
Sarepta Therapeutics anuncia convocatoria de solicitudes para el 7.º Route 79 anual, el Programa de Becas de Duchenne	29.02.
Sarepta Therapeutics Swings to Q4 Profit, Revenue Increases; Shares Rise After Market	28.02.
Sarepta Therapeutics: Q4 Earnings Snapshot	28.02.
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments	28.02.
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 Revenue $396.8M, vs. Street Est of $386.2M	28.02.
Earnings Flash (SRPT) SAREPTA THERAPEUTICS Posts Q4 EPS $0.82, vs. Street Est of $0.37	28.02.
Sarepta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sarepta Therapeutics, Inc.

Aktien

A1J1BH

US8036071004

SRPT

Andere Sprachen

Filter